Healthtech & Biotech
Precision medicine, AI-driven diagnostics, genomics platforms, and digital health infrastructure.
Healthcare technology and biotechnology are converging to create new paradigms in patient care, drug discovery, and health system efficiency. This vertical tracks companies at the intersection of biology, data science, and clinical innovation.
지난 7일간 Healthtech & Biotech 관련 시그널 41건이 추가되었습니다.
BeiGene's Novel BCL2 Inhibitor Sonrotoclax Receives First-in-World Approval
BeiGene's novel BCL2 inhibitor, Sonrotoclax, has received its first-in-world approval for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). This regulatory milestone signifies a significant advancement in B-cell malignancy treatment, offering a new therapeutic option for patients with limited alternatives. The approval is based on robust clinical trial data demonstrating efficacy and safety.
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines presented significant data at the 2025 American Society of Hematology (ASH) Annual Meeting, showcasing its leadership in the development of novel therapies for B-cell malignancies. The presentations highlighted advancements in its pipeline, including data on Sonrotoclax and BRUKINSA, underscoring the company's commitment to innovation in hematology.
M3 Inc. Announces FY2025 Q1 Consolidated Financial Results
M3 Inc. has announced its consolidated financial results for the first quarter of fiscal year 2025. The report details the company's financial performance, including key metrics such as revenue and profit. This disclosure provides investors and stakeholders with an early look at the company's performance for the fiscal year, enabling an assessment of its initial progress and strategic direction.
BRUKINSA Delivers Landmark 74% 6-Year PFS in Treatment-Naïve CLL
BeiGene announced landmark data from a Phase 3 study showing BRUKINSA achieved a 74% progression-free survival (PFS) rate at six years in patients with treatment-naïve chronic lymphocytic leukemia (CLL). This significant long-term efficacy data reinforces BRUKINSA's position as a leading treatment option for CLL.
BeOne Medicines to Announce Q4 and Full Year 2025 Financial Results
BeOne Medicines announced that it will release its fourth quarter and full year 2025 financial results on February 26, 2026. The company will also host a conference call to discuss the results. This announcement provides investors with advance notice of the upcoming earnings report and an opportunity to engage with management.
BRUKINSA Demonstrates Strong 6-Year PFS in Treatment-Naïve CLL Patients
BeOne Medicines announced landmark data showing BRUKINSA achieved a 74% 6-year progression-free survival (PFS) rate in patients with treatment-naïve chronic lymphocytic leukemia (CLL). These results, presented at ASH 2025, underscore BRUKINSA's long-term efficacy and durability as a foundational treatment for CLL, reinforcing its position in the market.
M3 Announces FY2025 Q3 Presentation Material
M3 Inc. has published the presentation materials accompanying its fiscal year 2025 third-quarter financial results. These materials typically offer a more detailed, visual, and narrative explanation of the company's performance, strategic initiatives, and future outlook. They are designed to provide stakeholders with a deeper understanding of the financial data and the underlying business drivers.
BeiGene Rebrands to BeOne Medicines, Relocates to Switzerland
BeiGene's U.S. subsidiary has officially changed its name to BeOne Medicines USA, Inc., effective March 17, 2025. This rebranding, along with a planned redomiciliation to Switzerland, is pending shareholder approval. The company stated the new name reflects its commitment to developing innovative medicines and partnering globally to assist cancer patients.
BeiGene Announces Q4 and Full Year 2025 Financial Results
BeiGene released its financial results for the fourth quarter and full year ended December 31, 2025. The report details the company's financial performance, including revenue, expenses, and profitability. This announcement is crucial for investors and stakeholders to assess BeiGene's financial health and strategic progress. The results provide insights into the company's operational efficiency and growth trajectory.
BeiGene's BRUKINSA Shows 74% 6-Year PFS in Treatment-Naïve CLL
BeiGene reported landmark 6-year progression-free survival (PFS) data for BRUKINSA (zanubrutinib) in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The data demonstrated a 74% PFS rate at six years, reinforcing BRUKINSA's efficacy and durability as a first-line treatment. This significant clinical outcome highlights the long-term benefit of BRUKINSA for CLL patients.
Zuellig Pharma Acquires Propan Brand in the Philippines
Zuellig Pharma has completed the acquisition of Propan, a leading multivitamin and appetite stimulant brand in the Philippines. This acquisition strengthens Zuellig Pharma's consumer health portfolio in the country, aiming to leverage the brand's established market position to further expand its reach and offerings in the Philippine healthcare landscape.
Zuellig Pharma and Organon Partner for Women's Health in Myanmar
Zuellig Pharma and Organon have formed a strategic partnership to expand access to women's health solutions in Myanmar. The collaboration focuses on addressing unintended pregnancies and improving reproductive health through enhanced distribution and educational initiatives, aiming to make essential products and information more readily available to women across the country.
Zuellig Pharma Launches Lilly's Obesity and Diabetes Medicine in Thailand
Zuellig Pharma has launched Eli Lilly's innovative obesity and diabetes medicine, Mounjaro® (tirzepatide), in Thailand. This marks a significant step in providing advanced treatment options for patients managing these chronic conditions, leveraging Zuellig Pharma's expertise in bringing novel pharmaceuticals to the Thai market and improving patient care.
PharmEasy Celebrates 11 Years of Simplifying Healthcare in India
PharmEasy, an Indian online healthcare aggregator, is celebrating its 11th anniversary. Since its launch in 2015, the company has focused on making healthcare accessible and affordable. It offers on-demand, home-delivered prescription pharmaceuticals, diagnostic tests, and OTC products across over 1000 cities in India. The milestone highlights their continued commitment to innovation and service expansion in the Indian healthcare market.
M3 Reports FY2024 Q4 Consolidated Financial Results
M3 Inc. has released its consolidated financial results for the fourth quarter of fiscal year 2024. The report details the company's financial performance, including revenue, profit, and other key financial metrics. This disclosure is important for investors and analysts to evaluate M3's annual performance and its strategic direction in the global digital health market.
M3 Announces FY2025 Q2 Consolidated Financial Results
M3 Inc. has published its consolidated financial results for the second quarter of fiscal year 2025. The report outlines the company's financial performance, including key indicators such as revenue and earnings. This update is essential for stakeholders to track M3's progress and evaluate its financial standing in the competitive digital health industry.
M3 Reports FY2025 Q1 Consolidated Financial Results
M3 Inc. has announced its consolidated financial results for the first quarter of fiscal year 2025. The report provides a comprehensive overview of the company's financial performance, including revenue, operating income, and net income. This disclosure is vital for stakeholders to assess M3's business momentum and its strategic positioning in the global digital health market.
Samsung Biologics and Eli Lilly to Establish New Gateway Labs in Korea
Samsung Biologics has entered into a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. This partnership aims to leverage Samsung Biologics' expertise to support Lilly's research and development activities, potentially accelerating drug discovery and development processes within the region.
Halodoc Achieves Regulatory Sandbox Supervision from Indonesian Ministry of Health
Halodoc has received "supervised" status in the Regulatory Sandbox program by the Ministry of Health of the Republic of Indonesia. This signifies a strong partnership and participatory supervision between Halodoc and the Ministry, aimed at safeguarding digital health innovation organizers, consumers, and healthcare workers.
Zuellig Pharma Opens Clinical Trial Support Center in South Korea
Zuellig Pharma has unveiled a new state-of-the-art Clinical Trial Support Innovation Center in South Korea. This facility is designed to bolster both domestic and global clinical research efforts by providing advanced infrastructure and services. The center aims to accelerate drug development and enhance the efficiency of clinical trials conducted within and beyond the Korean market.
Healius Lumus Imaging announces Annalise.ai partnership for AI-driven diagnostics
Healius' Lumus Imaging division has announced a partnership with Annalise.ai, a leader in artificial intelligence for medical imaging. This collaboration aims to integrate advanced AI solutions into Lumus Imaging's operations, enhancing diagnostic accuracy and efficiency. The partnership is expected to improve patient outcomes by enabling faster and more precise interpretations of medical scans across Healius' network.
M3 Inc. Reports FY2025 Q3 Consolidated Financial Results
M3 Inc. has released its consolidated financial results for the third quarter of fiscal year 2025. The report details the company's financial performance, including revenue, profit, and other key financial indicators. Investors and analysts will review these figures to assess M3's ongoing business trajectory and profitability. The results provide insights into the company's operational efficiency and market position during the specified period.
M3's VIDAL Group Acquires GPR for Renal Failure Support in France
M3 Inc.'s VIDAL Group has acquired GPR, a company specializing in prescription support tools for renal failure patients in France. This acquisition aims to enhance M3's healthcare offerings by integrating GPR's technology and patient support capabilities into its existing services. The move is expected to strengthen M3's position in the French pharmaceutical and patient support market, providing a more comprehensive solution for chronic kidney disease management.
Samsung Biologics Achieves Independent Validation for Product Carbon Footprint System
Samsung Biologics has received independent validation for its Product Carbon Footprint (PCF) system, demonstrating its commitment to climate transparency. This validation, achieved through collaboration with an external expert, allows the company to provide customers with accurate carbon footprint data for their products. This initiative supports sustainable supply chain management within the biopharmaceutical industry.
BeiGene Announces Fourth Quarter and Full Year 2025 Financial Results
BeiGene announced its financial results for the fourth quarter and full year of 2025. The company highlighted key achievements and financial performance, providing insights into its operational progress and strategic advancements in the oncology sector. This report offers stakeholders a comprehensive overview of BeiGene's financial health and its ongoing commitment to developing innovative cancer treatments.
BeiGene's Sonrotoclax Receives First-in-World Approval in R/R MCL
BeiGene announced that its novel BCL2 inhibitor, sonrotoclax, has received its first-in-world approval for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). This regulatory milestone signifies a significant advancement in the treatment landscape for patients with this aggressive form of non-Hodgkin lymphoma, offering a new therapeutic option.
BeOne Medicines Announces Q4 and FY2025 Financial Results
BeOne Medicines reported its fourth quarter and full year 2025 financial results, highlighting the global success of its product BRUKINSA and its leadership in foundational oncology. The company's performance underscores its strategic growth and market penetration in key therapeutic areas.
Sonrotoclax Receives First-in-World Approval for R/R MCL and R/R CLL/SLL
BeOne Medicines' novel BCL2 inhibitor, Sonrotoclax, has achieved first-in-world approval for the treatment of relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) and R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). This regulatory milestone marks a significant advancement in B-cell malignancy treatment.
BeiGene Granted U.S. FDA Fast Track Designation for BGB-B2033
BeOne Medicines has received U.S. FDA Fast Track Designation for BGB-B2033, an investigational treatment for Hepatocellular Carcinoma (HCC). This designation is granted to drugs that treat serious conditions and fill an unmet medical need, potentially expediting the development and review process.
Zuellig Pharma Acquires Zam-Buk and Vapex Brands from Bayer
Zuellig Pharma has strengthened its consumer healthcare portfolio by acquiring the Zam-Buk® and Vapex® brands from Bayer. This strategic acquisition aims to expand Zuellig Pharma's presence and offerings within the consumer healthcare market across Asia, leveraging the established brand recognition and market reach of the acquired products. The deal underscores Zuellig Pharma's commitment to growing its consumer health segment.
Zuellig Pharma Expands Lundbeck Partnership for Neuro-Psychiatric Solutions
Zuellig Pharma has expanded its partnership with Lundbeck to enhance the commercialization of neuro-psychiatric health solutions across Asia. This collaboration will leverage Zuellig Pharma's extensive distribution network and market expertise to bring innovative treatments for neurological and psychiatric conditions to a wider patient population. The expanded partnership aims to improve access to specialized healthcare solutions in the region.
Zuellig Pharma Opens Clinical Trial Support Innovation Center in South Korea
Zuellig Pharma has unveiled a state-of-the-art Clinical Trial Support Innovation Center in South Korea. This new facility is designed to bolster both domestic and global clinical research by providing advanced infrastructure and services. The center aims to accelerate the drug development process, support pharmaceutical companies in conducting efficient trials, and contribute to the advancement of medical research within the APAC region.
Healius Launches National Pharmacogenomic Awareness Campaign
Healius' Genomic Diagnostics division has initiated a national awareness campaign for Pharmacogenomic (PGx) testing. The campaign aims to educate patients about the benefits of simple DNA tests, encouraging wider adoption of personalized medicine approaches within Australia. This initiative seeks to improve patient outcomes by tailoring treatments based on individual genetic profiles.
Celltrion Commences Full-Scale CMO Production at U.S. Facility
Celltrion has begun full-scale production of Eli Lilly CMO products at its U.S. Branchburg facility, following acquisition and site preparations completed by January 2026. The company is also initiating validation for its own product manufacturing, aiming for a fully integrated U.S. supply system. This move is part of a strategy to mitigate U.S. tariff risks through local production and inventory.
Celltrion Announces 35th Annual General Meeting of Shareholders
Celltrion has announced its 35th Annual General Meeting of Shareholders, scheduled for March 24, 2026, at 10:00 AM KST in Incheon, Republic of Korea. Key agendas include reporting on the fiscal year 2025 audit and business, approving financial statements, amending articles of incorporation, electing directors and audit committee members, and approving director remuneration and treasury share plans.
Halodoc Reaches 35 Million Monthly Active Users, Launches AI Triage in Indonesia
Indonesian healthtech platform Halodoc has reached 35 million monthly active users and launched an AI-powered triage system that helps patients identify symptoms and route them to appropriate specialists. The AI triage system, developed in partnership with local medical institutions, supports Bahasa Indonesia and handles over 500,000 consultations per day.
Lunit's AI Cancer Detection Platform Receives FDA Clearance for Lung and Breast Screening
South Korean AI medical imaging company Lunit has received FDA 510(k) clearance for its Lunit INSIGHT CXR and Lunit INSIGHT MMG products, which use deep learning to detect lung nodules and breast cancer in X-ray and mammography images. The clearance opens the US market for Lunit, which already has regulatory approvals in 50+ countries and partnerships with GE HealthCare and Fujifilm.
Samsung Biologics Signs $2.2B CDMO Deal with Major US Pharma Company
Samsung Biologics has signed a $2.2 billion contract development and manufacturing organization (CDMO) deal with an undisclosed major US pharmaceutical company. The multi-year agreement covers biologics manufacturing at Samsung's Songdo campus, which will have total capacity of 784,000 liters upon completion of Plant 4. This is the largest single CDMO contract in the company's history.
BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants
BeiGene's anti-PD-1 antibody tislelizumab has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of non-small cell lung cancer. This marks a significant milestone as a Chinese-developed immunotherapy gains approval in one of the world's most stringent regulatory markets, directly competing with Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
Biocon Biologics Completes Integration of Viatris Biosimilars, Becomes World's Largest
Biocon Biologics has completed the integration of Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with a portfolio of 20+ molecules and commercial presence in 120+ countries. The combined entity reported annualized revenue of $2.1 billion and aims to make biologics accessible to patients across emerging markets in Asia, Africa, and Latin America.
WuXi Biologics Expands Global CDMO Network with New Facility in Singapore
WuXi Biologics has announced the expansion of its global Contract Development and Manufacturing Organization (CDMO) network with a new state-of-the-art biologics manufacturing facility in Singapore. The facility will serve as a key hub for the company's Southeast Asian and global operations, strengthening its capabilities in antibody and cell therapy manufacturing.
Get the latest signals from this industry delivered to your inbox.
Foundation models, enterprise AI, and the infrastructure powering the next wave of machine intelligence.
Digital payments, neobanking, DeFi infrastructure, and the transformation of financial services.
Electric vehicles, autonomous driving, battery technology, and next-generation transportation networks.
Clean energy, carbon capture, grid modernization, and the industrial shift toward sustainability.
SaaS platforms, developer tools, workflow automation, and enterprise infrastructure modernization.
Healthtech & Biotech의 모든 시그널을 아카이브에서 확인하세요.
View in Signal Archive